全文获取类型
收费全文 | 944篇 |
免费 | 36篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 38篇 |
妇产科学 | 3篇 |
基础医学 | 82篇 |
口腔科学 | 10篇 |
临床医学 | 61篇 |
内科学 | 216篇 |
皮肤病学 | 7篇 |
神经病学 | 15篇 |
特种医学 | 317篇 |
外科学 | 163篇 |
综合类 | 13篇 |
预防医学 | 25篇 |
眼科学 | 3篇 |
药学 | 33篇 |
中国医学 | 1篇 |
肿瘤学 | 14篇 |
出版年
2021年 | 13篇 |
2019年 | 2篇 |
2018年 | 13篇 |
2017年 | 8篇 |
2016年 | 2篇 |
2015年 | 8篇 |
2014年 | 7篇 |
2013年 | 17篇 |
2012年 | 21篇 |
2011年 | 9篇 |
2010年 | 24篇 |
2009年 | 22篇 |
2008年 | 10篇 |
2007年 | 27篇 |
2006年 | 11篇 |
2005年 | 15篇 |
2004年 | 9篇 |
2003年 | 17篇 |
2002年 | 13篇 |
2001年 | 19篇 |
2000年 | 13篇 |
1999年 | 19篇 |
1998年 | 49篇 |
1997年 | 41篇 |
1996年 | 60篇 |
1995年 | 48篇 |
1994年 | 38篇 |
1993年 | 38篇 |
1992年 | 19篇 |
1991年 | 25篇 |
1990年 | 25篇 |
1989年 | 41篇 |
1988年 | 42篇 |
1987年 | 30篇 |
1986年 | 27篇 |
1985年 | 39篇 |
1984年 | 20篇 |
1983年 | 22篇 |
1982年 | 26篇 |
1981年 | 24篇 |
1980年 | 12篇 |
1979年 | 3篇 |
1978年 | 5篇 |
1977年 | 26篇 |
1976年 | 19篇 |
1975年 | 14篇 |
1967年 | 1篇 |
1936年 | 1篇 |
1934年 | 1篇 |
1933年 | 1篇 |
排序方式: 共有1002条查询结果,搜索用时 0 毫秒
41.
42.
43.
ER Brown KA Charles SA Hoare RL Rye DI Jodrell RE Aird R Vora U Prabhakar M Nakada RE Corringham M DeWitte C Sturgeon D Propper FR Balkwill JF Smyth 《Annals of oncology》2008,19(7):1340-1346
BACKGROUND: Tumour necrosis factor-alpha (TNF-alpha) is an important regulator of the chronic inflammation contributing to tumour progression. Infliximab, an anti-TNF-alpha monoclonal antibody was investigated in this trial of patients with advanced cancer. The primary objectives were to determine the safety profile and biological response of infliximab in a cancer population. Clinical response was a secondary objective. PATIENTS AND METHODS: Forty-one patients received infliximab at 5 mg/kg (n = 21) or 10 mg/kg (n = 20) i.v. at 0 and 2 weeks and then every 4 weeks. Post-treatment samples were measured for changes in plasma and serum TNF-alpha, CCL2, IL-6 and C-reactive protein (CRP). RESULTS: Infliximab was well tolerated with no dose-limiting toxic effects. At both doses of infliximab, neutralisation of serum TNF-alpha was observed after 1 h while plasma CCL2, IL-6 and serum CRP were decreased 24 and 48 h following infliximab administration. Seven patients experienced disease stablisation (range 10-50+ weeks). There was no evidence of disease acceleration in any patient. CONCLUSIONS: Infliximab treatment was safe and well tolerated in patients with advanced cancer. There was evidence of biological activity with baseline TNF-alpha and CCL2 being correlated with infliximab response. 相似文献
44.
45.
46.
Vilchez RA McEllistrem MC Harrison LH McCurry KR Kormos RL Kusne S 《The Annals of thoracic surgery》2001,72(1):96-101
BACKGROUND: Ventricular assist devices (VAD) are currently approved for use as a bridge for transplantation. Although reports have suggested acceptable rates of survival of patients with VAD, there is little information regarding the mechanism and etiology of bacteremia in these patients. METHODS: We prospectively followed patients who underwent VAD implantation and developed bacteremia during VAD support at the University of Pittsburgh Medical Center. Relapsing bacteremia was defined as at least two episodes of positive blood cultures with a genetically related organism on 2 different days. Species identification and susceptibility testing were performed on all isolates. Pulse field gel electrophoresis was performed on selected blood and VAD isolates. RESULTS: Between January 1998 and August 1999, 3 patients with VAD developed relapsing bacteremia, which was treated with full courses of antibiotic agents, 2 of whom also developed VAD endocarditis. All 3 patients had documented driveline or device pocket infections with these isolates. Consecutive blood and VAD isolates were found to be genetically related within each patient. CONCLUSIONS: These patients with bacteremia after VAD implantation had relapse due to the same strain, which may have originated from indolent driveline infection. Endovascular infection in this setting is difficult to eradicate with antibiotic agents and carries a high mortality. These patients should be considered to have priority for orthotopic heart transplantation. 相似文献
47.
48.
49.
50.